Evaluation Of Rhodiola Rosea Supplementation On Skeletal Muscle Damage And Inflammation In Runners Following A Competitive Marathon

Effect Both
Values Figure 3
Trial Design Randomized trial
Trial Length 2-4 Weeks
Number of Subjects 55
Sex Both Genders
Age Range 18-29, 30-44, 45-64, 65+
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 55 marathon runners were allocated to take 300 mg of Rhodiola Rosea extract (11.3 mg rosavin, 4.3 mg salidroside) twice daily for 30 days prior to the marathon and 7 days after.

Muscle function as measured by the vertical jump test, didn't differ significantly between groups, and neither did the symptoms of DOMS. There was a nonsignificantly greater increase in creatine kinase in the Rhodiola group compared with placebo after the marathon, and there were no statistically significant differences between groups in neutrophils, lymphocytes, monocytes, AST, or ALT, as well as any cytokines or measures of inflammation, though modestly higher inflammation was found in the placebo group.
Funding issues for this study:
"This study was funded through a grant provided by PL Thomas & Co., Inc. (Morristown New Jersey)."